Understanding how CGRP affects autonomic function in migraine patients
Official title: Autonomic Functions in Migraine Patients as a Function of Migraine Status and CGRP Inhibition
Run by Medical University of Vienna · NCT04628429 · Data updated 2026-11-12
This study is trying to see how a migraine treatment affects the nervous system in people with migraines, both during attacks and when they're feeling fine.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 64 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Medical University of Vienna Academic / other |
| Drugs / interventions | Erenumab, Galcanezumab, Fremanezumab, Eptinezumab |
| Locations | 1 site (Vienna) |
| Status | Recruiting |
| Started | October 1, 2020 |
| Main results expected | December 2025 |
| Study ends | December 2026 |
| Registry record updated | December 10, 2024 |
| Trial ID | NCT04628429 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with chronic or episodic migraines who have not responded to multiple prophylactic treatments.
✕Probably not a fit
Patients with a history of certain cardiovascular conditions or those who are pregnant or lactating may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the role of the autonomic nervous system in patients suffering from episodic and chronic migraines. It will assess whether autonomic functions vary based on migraine status, such as during an attack or in between attacks, and how these functions may be influenced by CGRP monoclonal antibodies. The study will utilize standardized autonomic tests and scales to evaluate symptoms and gather data on the impact of CGRP inhibition on autonomic function. The findings could provide insights into the relationship between migraines and autonomic symptoms.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of migraine mechanisms and lead to improved treatment strategies for patients.
How similar studies have gone: While there have been studies on CGRP's role in migraines, this specific focus on autonomic function is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic migraine according to ICHD-3 * Episodic migraine without aura or with aura according to ICHD-3 * Unsuccessful treatment with 3 or more established prophylactic drugs * Medicine costs are covered by health insurance * Healthy controls must be free from any diagnosed chronic disease or acute infection requiring medication Exclusion Criteria: * Pregnancy and lactation * Neurosurgical interventions performed within the last 12 months * Coronary bypass surgery or revascularization procedures performed within the last 12 months * History of transient ischemic attacks (TIA), stroke, stable or unstable angina pectoris, myocardial infarction or uncontrolled hypertension * Known hypersensitivity to therapy with an anti-CGRP Antibodies * History of a disorder (other than migraine) that may affect the results of autonomic tests * Healthy controls must have no personal or family history of migraine
Where it's running
-
Medical University of Vienna
Vienna, Austria Recruiting
Study contacts
- Principal investigator: Christian Wöber, Prof. MD — Medical University of Vienna
- Study coordinator: Antun R Pavelic, MD
- Email: antun.pavelic@meduniwien.ac.at
- Phone: +43 (0)1 40400 - 31170
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
i-NEED: New migraine drugs database
This project will collect real-life data to see how new migraine treatments—anti‑CGRP antibodies, gepants, ditans, and a sumatriptan‑naproxen combo—work and how well adults with episodic or chronic migraine tolerate them.
-
Assessing the safety and effectiveness of Atogepant for migraine prevention in Korean adults
This study is testing how well and safely Atogepant works for preventing migraines in Korean adults who have chronic or episodic migraines.
-
Nebulized dexmedetomidine for early chronic migraine
This study tests whether inhaled dexmedetomidine can lessen central sensitization and help prevent chronification in people with early chronic migraine.
-
Gou-Teng-San (GTS) for adults with episodic migraine
This trial will test whether the herbal formula Gou-Teng-San (GTS) can reduce migraine attacks and symptoms in adults with episodic migraine.
-
Real-world use of anti-CGRP medicines for preventing migraine
This project will follow people with episodic or chronic migraine who start anti-CGRP medicines to see if the treatments reduce migraine frequency and side effects over two years.
-
Suppressive Functions of Regulatory T Cells in Migraine
This study tests whether regulatory T cells can help control migraine-related inflammation in adults with chronic migraine.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.